Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Neurocrine Biosciences Inc (NBIX) – Neurocrine Biosciences Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Neurocrine Biosciences (NBIX) trades at $149.59, up 1.75% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 98.17% gross margins and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.68 expected. Recent developments include the $2.9 billion acquisition of Soleno Therapeutics and positive clinical data for CRENESSITY, positioning for growth in rare disease treatments.
NBIX presents a compelling growth story with 86% analyst buy ratings and a $184 consensus target suggesting 23% upside. Key risks include integration challenges from the Soleno acquisition and potential volatility near 52-week highs. The combination of strong profitability, pipeline advancements, and institutional support supports a positive medium-term outlook despite elevated valuation multiples.
Read full analysis

Key Stats

  • Market Cap
    $15.31B
  • Sector
    Health
  • 3M Drawdown
    -10.57%
  • Enterprise Value
    $14.40B
  • Dividend Yield
    -
  • Typical Hold Time
    1 days
$152.25
52W Low: $115.71
09 May 2025
52W High: $155.63
10 Dec 2025

Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $15.31B, with an enterprise value of $14.40B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $115.71 and a high of $155.63, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -10.57%, reflecting recent price volatility. On average, investors hold Neurocrine Biosciences Inc for approximately 1 days, indicating typical investor behavior on the platform.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.


Technical Indicators
|
|
|
Overall Summary
Bearish (6)Neutral (9)Bullish (12)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $15.31B
  • Sector
    Health
  • 3M Drawdown
    -10.57%
  • Enterprise Value
    $14.40B
  • Dividend Yield
    -
  • Typical Hold Time
    1 days
$152.25
52W Low: $115.71
09 May 2025
52W High: $155.63
10 Dec 2025

Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $15.31B, with an enterprise value of $14.40B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $115.71 and a high of $155.63, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -10.57%, reflecting recent price volatility. On average, investors hold Neurocrine Biosciences Inc for approximately 1 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!